Stroke patients without occlusions treated via thrombolysis fared better than patients who weren’t in a study published online July 29 in Stroke.

With surgery and introduction of a foreign object into a patient always comes some risk of infection. However, according to a study published online July 31 in Circulation, reducing that risk may involve more than just a clean site.

The Transcatheter Cardiovascular Therapeutics (TCT) conference announced its lineup for late-breaking clinical trials and first report investigations that will be a presented Sept. 13-15 at the scientific sessions in Washington, D.C.

Neighborhood effects may have an influence on readmissions in patients with heart failure. Whether or not patients themselves have a higher socioeconomic status, where they live may play a role in their post-release outcomes, according to a study published online July 29 in Circulation: Cardiovascular Quality & Outcomes.

Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults. The European Commission approval applies to all European Union (EU) member states as well as Iceland and Norway. Eliquis is also approved in the EU for the prevention of venous thromboembolism (VTE) in adults who have undergone elective total hip or knee replacement surgery, and for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors.

Lowering the amount of contrast used and encouraging more oral hydration before and after a PCI procedure reduced contrast-induced acute kidney injury by 21 percent, according to a study published online July 29 in Circulation: Cardiovascular Quality and Outcomes. 

Initiatives to provide timely treatment for patients with acute MI overall appear to making an impact but hospitals still have room to improve in their care of patients who present off-hours, an analysis published online July 29 in Circulation: Cardiovascular Quality and Outcomes suggests.

Cardioxyl Pharmaceuticals, Inc. announced today the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers. The company has now initiated dosing of hospitalized patients with decompensated heart failure in a Phase IIa clinical trial designed to further evaluate the drug’s safety and tolerability as well as its dosing levels.